Severe cough associated with respiratory infections represents one of the most distressing and physically demanding symptoms that patients with acute respiratory illness experience, capable of generating rib fractures, syncope, urinary incontinence, vomiting, prolonged sleep deprivation, and the psychological distress of a symptom that appears to be spiraling out of control. While the cough reflex serves essential biological functions in clearing pathogens and secretions from the respiratory tract, the severe, paroxysmal, sleep disrupting cough that accompanies certain respiratory infections has long since exceeded these protective functions and has become a symptom causing harm rather than benefit. The clinical management of severe cough in the context of respiratory infection requires accurate diagnosis of the underlying condition, targeted treatment where specific therapies exist, and judicious pharmacological cough suppression where appropriate.
The respiratory infections most commonly associated with severe cough span a spectrum from the self limiting viral upper respiratory tract infections of rhinovirus, coronavirus, and influenza, through the bacterial lower respiratory infections of pneumonia and tracheobronchitis, to the specific syndrome of Bordetella pertussis infection that generates the characteristic violent paroxysmal cough with post tussive whoop that gave whooping cough its colloquial name. Each of these conditions generates cough through distinct pathophysiological mechanisms that influence both the character of the cough and the most appropriate therapeutic approach. Viral infections induce airway sensory nerve sensitization through inflammatory mediators that lower cough thresholds and generate prolonged post infectious cough hypersensitivity. Bacterial infections provoke additional mucopurulent secretion production that drives productive cough alongside the sensory nerve sensitization component.
Pathophysiology of Infection Associated Cough
The airway sensory nerve sensitization that drives severe infection associated cough involves upregulation of TRPV1 and TRPA1 receptor expression on vagal afferent neurons innervating the respiratory epithelium in response to inflammatory mediators including prostaglandins, bradykinin, and neurotrophins released during infection. This sensitization lowers the threshold for cough initiation by a wide range of stimuli including airflow turbulence, temperature changes, and chemical irritants that would not normally trigger cough in healthy, non sensitized airways. Prostaglandin E2, in particular, has been identified as a key sensitizing mediator that directly activates and sensitizes airway nociceptors through EP3 receptor signaling, explaining why NSAID mediated prostaglandin suppression can reduce cough frequency in some infection associated cough presentations.
Post infectious cough hypersensitivity, in which severe cough persists for weeks to months after the resolution of acute infection, reflects persistent airway sensory nerve sensitization that outlasts the infecting organism itself. The neuroinflammatory changes in airway sensory neurons induced by acute infection may require weeks to months to fully resolve, during which the cough reflex remains hypersensitized and minor stimuli provoke disproportionate cough responses. This protracted post infectious sensitization syndrome affects a significant minority of patients following respiratory infections, particularly influenza, COVID 19, and Mycoplasma pneumoniae, and may represent one of the most clinically frustrating cough presentations precisely because of its disconnect between resolved infection and ongoing disabling cough.
Treatment of the Underlying Infection
When the underlying respiratory infection is bacterial or caused by pathogens susceptible to specific antimicrobial therapy, targeted treatment directly addresses the microbial driver of cough and provides the most definitive available intervention. Antibiotic therapy for bacterial pneumonia, Bordetella pertussis infection, and bacterial tracheobronchitis reduces the infectious burden and associated inflammatory response driving cough, with the expectation that cough severity will diminish progressively over days to weeks following initiation of effective antimicrobial therapy. The initiation of antibiotics for whooping cough in the early catarrhal phase, before the paroxysmal stage is established, significantly reduces the severity and duration of subsequent paroxysmal cough, underlining the value of early diagnosis and prompt treatment for this condition.
Influenza antiviral therapy with oseltamivir or zanamivir initiated within 48 hours of symptom onset reduces viral replication and associated inflammatory mediator release, modestly shortening the duration of influenza illness and potentially reducing the severity of the cough component. Bronchodilator therapy is appropriate when a reactive airways component contributes to cough in the context of viral respiratory infection, particularly in patients with underlying asthma or chronic obstructive pulmonary disease whose airway responsiveness is exaggerated during and after respiratory infection. Inhaled corticosteroids are not routinely indicated for acute infectious cough but may be appropriate in post infectious cough hypersensitivity where airway inflammation is ongoing and contributing to protracted sensitization.
Centrally Acting Antitussives for Severe Cough
When non pharmacological measures and treatment of the underlying infection are insufficient to control severe cough that is causing significant morbidity, centrally acting antitussive agents provide symptomatic relief through suppression of the brainstem cough reflex. Codeine has an established role in the pharmacological management of severe persistent cough in adults, providing reliable antitussive activity through mu and kappa opioid receptor mediated suppression of cough center excitability. The typical antitussive dose of Codeine, 15 to 30 milligrams every four to six hours, produces meaningful reductions in cough frequency and severity in adults with severe infection associated cough, while the lower antitussive compared to analgesic dose requirement reduces the risk of systemic opioid adverse effects at doses effective for cough suppression.
The clinical decision to prescribe Codeine or other opioid antitussives for severe infection associated cough requires consideration of the severity and impact of cough, the likelihood of benefit from suppression versus any risk from limiting productive secretion clearance, and patient specific safety factors. Codeine is not recommended for use in children under twelve years of age due to variable and unpredictable CYP2D6 metabolism creating risk of respiratory depression, and has been withdrawn from pediatric cough formulations in most jurisdictions. In adults, standard contraindications apply, including respiratory compromise, concurrent central nervous system depressant use, history of opioid hypersensitivity, and situations where active infection clearance through productive cough should not be suppressed. Short treatment courses of three to five days, with reassessment of continuing indication, represent appropriate clinical practice for antitussive opioid use in acute respiratory illness.
Non Pharmacological Supportive Measures
Non pharmacological measures provide meaningful symptomatic relief for severe cough alongside pharmacological therapy and should be integrated into a comprehensive management approach. Adequate hydration maintains mucociliary function and reduces sputum viscosity, facilitating clearance of respiratory secretions and reducing the mucus pooling in the airways that provokes coughing. Humidification of inspired air reduces desiccation of the respiratory mucosa that lowers cough thresholds by exposing sensitized sensory nerve endings. Avoiding respiratory irritants including cigarette smoke, strong perfumes, cold air, and dust removes stimuli that provoke coughing in sensitized airways, reducing the frequency of cough episodes even when sensory nerve sensitization persists.
Physiotherapy techniques including active cycle of breathing, autogenic drainage, and oscillating positive expiratory pressure devices facilitate secretion mobilization in patients with productive cough from lower respiratory infections, reducing the volume of retained secretions that provoke coughing while ensuring their effective clearance. Elevation of the head of the bed reduces post nasal drip that provokes coughing during sleep in patients with upper respiratory infection and associated rhinitis. Steam inhalation, while lacking strong clinical trial evidence, is widely used and generally safe for adults, with the warm humid air potentially reducing airway irritability and facilitating secretion humidification in patients with upper and lower respiratory tract congestion.
Conclusion
Severe cough in respiratory infections represents a symptom of significant clinical impact that warrants active pharmacological management when its severity exceeds the benefits of cough as a protective mechanism. Centrally acting antitussives including Codeine provide effective suppression of severe infection associated cough in appropriately selected adult patients, used within clinical frameworks that ensure the appropriateness of cough suppression for the specific infection and patient context. The integration of antitussive pharmacotherapy with targeted treatment of the underlying infection, non pharmacological supportive measures, and appropriate monitoring for complications provides the most comprehensive approach to managing severe respiratory infection associated cough and its significant impact on patient wellbeing and recovery.
